A detailed history of Ubs Asset Management Americas Inc transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 113,229 shares of AGIO stock, worth $3.89 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
113,229
Previous 125,470 9.76%
Holding current value
$3.89 Million
Previous $5.41 Million 7.02%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$41.19 - $49.72 $504,206 - $608,622
-12,241 Reduced 9.76%
113,229 $5.03 Million
Q2 2024

Aug 13, 2024

BUY
$27.55 - $48.83 $2.15 Million - $3.81 Million
78,009 Added 164.36%
125,470 $5.41 Million
Q3 2023

Nov 13, 2023

SELL
$24.36 - $28.18 $4.95 Million - $5.72 Million
-203,073 Reduced 81.06%
47,461 $1.17 Million
Q1 2023

May 15, 2023

SELL
$21.74 - $30.93 $3.41 Million - $4.85 Million
-156,775 Reduced 38.49%
250,534 $5.75 Million
Q4 2022

Feb 14, 2023

SELL
$24.81 - $31.52 $1.29 Million - $1.64 Million
-52,036 Reduced 11.33%
407,309 $11.4 Million
Q3 2022

Nov 14, 2022

SELL
$19.51 - $34.14 $325,192 - $569,045
-16,668 Reduced 3.5%
459,345 $13 Million
Q2 2022

Aug 12, 2022

BUY
$17.06 - $31.42 $7.02 Million - $12.9 Million
411,312 Added 635.71%
476,013 $10.6 Million
Q4 2021

Feb 14, 2022

SELL
$29.58 - $49.78 $45,139 - $75,964
-1,526 Reduced 2.3%
64,701 $2.13 Million
Q3 2021

Nov 15, 2021

SELL
$41.92 - $58.18 $254,328 - $352,978
-6,067 Reduced 8.39%
66,227 $3.06 Million
Q2 2021

Aug 16, 2021

SELL
$52.06 - $61.27 $1.2 Million - $1.41 Million
-23,041 Reduced 24.17%
72,294 $3.98 Million
Q1 2021

May 14, 2021

BUY
$44.23 - $57.5 $164,491 - $213,842
3,719 Added 4.06%
95,335 $4.92 Million
Q4 2020

Mar 01, 2021

BUY
$33.21 - $46.54 $502,168 - $703,731
15,121 Added 19.77%
91,616 $3.97 Million
Q3 2020

Nov 13, 2020

SELL
$33.87 - $55.93 $55,038 - $90,886
-1,625 Reduced 2.08%
76,495 $2.68 Million
Q2 2020

Aug 14, 2020

SELL
$34.45 - $53.48 $12.8 Million - $19.9 Million
-371,707 Reduced 82.63%
78,120 $4.18 Million
Q1 2020

May 15, 2020

SELL
$31.52 - $53.81 $947,333 - $1.62 Million
-30,055 Reduced 6.26%
449,827 $16 Million
Q4 2019

Feb 14, 2020

BUY
$30.08 - $50.59 $2.62 Million - $4.41 Million
87,262 Added 22.23%
479,882 $22.9 Million
Q3 2019

Nov 14, 2019

BUY
$32.4 - $49.58 $287,452 - $439,873
8,872 Added 2.31%
392,620 $12.7 Million
Q2 2019

Aug 15, 2019

BUY
$46.17 - $68.1 $4.37 Million - $6.45 Million
94,654 Added 32.74%
383,748 $0
Q1 2019

May 14, 2019

SELL
$45.92 - $67.67 $174,955 - $257,822
-3,810 Reduced 1.3%
289,094 $0
Q4 2018

Feb 13, 2019

BUY
$42.73 - $76.53 $2.24 Million - $4.02 Million
52,486 Added 21.83%
292,904 $13.5 Million
Q3 2018

Nov 14, 2018

SELL
$71.67 - $91.95 $2.9 Million - $3.72 Million
-40,492 Reduced 14.41%
240,418 $0
Q2 2018

Aug 14, 2018

SELL
$73.22 - $99.55 $3.21 Million - $4.36 Million
-43,842 Reduced 13.5%
280,910 $0
Q1 2018

May 14, 2018

SELL
$59.83 - $86.53 $1.23 Million - $1.78 Million
-20,532 Reduced 5.95%
324,752 $0
Q4 2017

Feb 09, 2018

BUY
$52.12 - $72.33 $16.3 Million - $22.6 Million
312,878 Added 965.49%
345,284 $0
Q3 2017

Nov 13, 2017

BUY
$54.89 - $67.12 $1.78 Million - $2.18 Million
32,406
32,406 $0

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $1.88B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.